Loading...
Please wait, while we are loading the content...
Similar Documents
Prognostic significance of total metabolic tumor volume on 18F-fluorodeoxyglucose positron emission tomography/ computed tomography in patients with diffuse large B-cell lymphoma receiving rituximab-containing chemotherapy.
| Content Provider | Europe PMC |
|---|---|
| Author | Chang, Chin-Chuan Cho, Shih-Feng Chuang, Ya-Wen Lin, Chia-Yang Chang, Shu-Min Hsu, Wen-Ling Huang, Ying-Fong |
| Copyright Year | 2017 |
| Abstract | PurposeThe purpose of this study was to determine the prognostic significance of metabolic parameters on pre-treatment 18F-fluorodeoxyglucose positron emission tomography/ computed tomography (FDG PET/CT), in patients with diffuse large B-cell lymphoma (DLBCL) receiving rituximab-containing therapy.Materials and MethodsFrom September 2009 to December 2014, DLBCL patients who had received FDG PET/CT scans for staging were enrolled. The maximal standardized uptake value of tumor (SUVt) was recorded. The metabolic tumor volume (MTV) was the volume of lesion with an elevated SUV greater than 2.5. The total lesion glycolysis (TLG) was the sum of the products of MTV and mean SUV in all measured lesions. Univariate and multivariate analyses were used to assess the prognostic significance of maximal SUVt, total MTV, TLG and other clinical parameters.ResultsThere were 118 patients enrolled in this study. The median follow-up time was 28.7 months. The 5-year progression-free survival (PFS) for patients with higher and lower total MTV was 32.3% and 66.0% respectively (p = 0.0001). The 5-year overall survival (OS) for patients with higher and lower total MTV was 34.3% and 69.9% respectively (p < 0.0001). Multivariate analysis revealed, besides IPI, that total MTV was independently predictive for PFS (HR: 2.31, 95% CI: 1.16 – 4.60, p = 0.0180) and OS (HR: 2.38, 95% CI: 1.12 – 5.04, p = 0.024). TLG and maximal SUV of tumor were not independent prognostic factors.ConclusionsAn elevated total MTV was a predictor for shorter PFS and OS in patients with DLBCL receiving rituximab-containing therapy, independent of IPI. |
| Journal | Oncotarget |
| Volume Number | 8 |
| PubMed Central reference number | PMC5725117 |
| Issue Number | 59 |
| PubMed reference number | 29245926 |
| e-ISSN | 19492553 |
| DOI | 10.18632/oncotarget.20447 |
| Language | English |
| Publisher | Impact Journals LLC |
| Publisher Date | 2017-08-24 |
| Access Restriction | Open |
| Rights License | This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Copyright: © 2017 Chang et al. |
| Subject Keyword | diffuse large B-cell lymphoma MTV TLG FDG PET/CT prognosis |
| Content Type | Text |
| Resource Type | Article |
| Subject | Oncology |
